GA-IDEMIA
10.2.2021 14:02:11 CET | Business Wire | Press release
Honeywell (NYSE: HON) , a global leader in connected buildings, and IDEMIA, the global leader in Augmented Identity, today announced a strategic alliance to create and cultivate an intelligent building ecosystem that provides a more seamless and enhanced experience for operators and occupants alike. The alliance will integrate Honeywell’s security and building management systems with IDEMIA’s biometric-based access control systems to create frictionless, safer and more efficient buildings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210210005454/en/
The Honeywell and IDEMIA alliance is intended to design solutions that will allow occupants to easily and securely have contactless engagement with a building – from vehicle recognition at the car park and automatic elevator calls to biometric-based access and personalized conference room settings. With a focus on security and data privacy, these next-generation solutions will provide occupants with a safer, more efficient and more enjoyable experience that will help building owners attract tenants.
“We recognize that our customers need to deliver business outcomes like managing complex security requirements and providing healthier, more productive environments,” said Manish Sharma, vice president, chief technology and chief product officer for Honeywell Building Technologies. “By working with IDEMIA we will create an intelligent building ecosystem that better addresses our customers’ key challenges and drives their desired outcomes. Whether it’s a commercial office building, a hospital or an airport, we have the ability to change the way people experience and interact with buildings for the better.”
“We look forward to expanding our long-standing relationship with Honeywell to bring greater value to our customers with more integrated solutions that make for a more seamless building experience,” said Matt Cole, CEO, Secure Enterprise Transactions Division, IDEMIA. “The ability for our technology to easily integrate with Honeywell safety and security systems will provide building owners and operators more insight and control into creating more efficient buildings, while putting the occupant experience first.”
IDEMIA’s field-proven AI-based products and solutions -- like MorphoWave TM , a contactless fingerprint device that scans four fingerprints in less than one second; VisionPass, the most advanced facial recognition terminal; or Augmented Vision, a biometric video analytics platform -- integrate with Honeywell security and building management systems. Honeywell’s systems include Pro-Watch Integrated Security Suite, MAXPRO Cloud and Enterprise Buildings Integrator.
Honeywell and IDEMIA will work together to deliver more powerful integrations through aligned product creation and joint product roadmaps. The integrated offerings will allow building operators to respond rapidly and effectively to alarms or incidents by providing an incident workflow package that allows Standard Operating Procedures (SOPs) to be configured, reducing compliance exceptions, security risks and response times.
IDEMIA products also support Honeywell’s Healthy Buildings solutions that help building owners improve building environments, operate more cleanly and safely and encourage sustained compliance with changing building standards, safety guidelines, government-issued regulations and a company's risk management policies. Honeywell's Healthy Buildings solutions provide a holistic view of a building's health based on key factors such as indoor air quality, occupant flow, personal protection equipment (PPE) analytics, contactless access, thermal screening, social distancing and sanitation efficacy.
To learn more about Honeywell and IDEMIA collaborations click here .
# # #
About IDEMIA
IDEMIA, the global leader in augmented identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for augmented identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide augmented identity for international clients from financial, telecom, identity, public security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com or follow @IDEMIAGroup on Twitter.
About Honeywell Building Technologies
Honeywell Building Technologies (HBT) is a global business with more than 18,000 employees. HBT creates products, software and technologies found in more than 10 million buildings worldwide. Commercial building owners and operators use our technologies to help create safe, energy efficient, sustainable and productive facilities. For more news and information on Honeywell Building Technologies, visit http://www.honeywell.com/newsroom .
Honeywell (www.honeywell.com ) is a Fortune 100 technology company that delivers industry specific solutions that include aerospace products and services; control technologies for buildings and industry; and performance materials globally. Our technologies help aircraft, buildings, manufacturing plants, supply chains, and workers become more connected to make our world smarter, safer, and more sustainable. For more news and information on Honeywell, please visit www.honeywell.com/newsroom .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005454/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
